When MorphoSys acquired Cambridge, Massachusetts-based Constellation Pharmaceuticals last year, the $1.7 billion deal value represented the entirety of the cancer drug developer’s pipeline ...

In the sky, the constellation of Cancer is practically an empty space in the sky, positioned between the Twin Stars (Pollux and Castor) of Gemini and the Sickle of Leo.

Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise ...

MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the ...

Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer First solid tumor study from company’s EZH2 ...